123,779 results match your criteria Alzheimers & Dementia[Journal]

Deep Recurrent Model for Individualized Prediction of Alzheimer's Disease Progression.

Neuroimage 2021 May 12:118143. Epub 2021 May 12.

Department of Brain and Cognitive Engineering, Korea University, Seoul 02841, Republic of Korea; Department of Artificial Intelligence, Korea University, Seoul 02841, Republic of Korea.

Alzheimer's disease (AD) is known as one of the major causes of dementia and is characterized by slow progression over several years, with no treatments or available medicines. In this regard, there have been efforts to identify the risk of developing AD in its earliest time. While many of the previous works considered cross-sectional analysis, more recent studies have focused on the diagnosis and prognosis of AD with longitudinal or time series data in a way of disease progression modeling. Read More

View Article and Full-Text PDF

In-vitro evaluation of antioxidant and anticholinesterase activities of novel pyridine, quinoxaline and s-triazine derivatives.

Environ Res 2021 May 12:111320. Epub 2021 May 12.

Department of Chemistry, Organic and Biomolecular Chemistry Laboratories, Yogi Vemana University, Kadapa-516005, Andhra Pradesh, India.

Cholinesterase enzymes such as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) cause hydrolysis of acetylcholine (ACh), a neurotransmitter responsible for the cognitive functions of the brain such as acquiring knowledge and comprehension. Therefore, inhibition of these enzymes is an effective process to curb the progressive and fatal neurological Alzheimer's disease (AD). Herein, we explored the potential inhibitory activities of various pyridine, quinoxaline, and triazine derivatives (3a-k, 6a-j and 11a-h) against AChE and BuChE enzymes by following the modified Ellman's method. Read More

View Article and Full-Text PDF

Investigation of therapeutic effect of Curcumin α and β Glucoside anomers against Alzheimer's disease by the nose to brain drug delivery.

Brain Res 2021 May 12:147517. Epub 2021 May 12.

Zanjan Applied Pharmacology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran; Department of Pharmacology and toxicology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.

Alzheimer's disease (AD) is one of the greatest geriatric medicinal challenges of our century and is the main disease leading to dementia. Despite extensive scientific research advances, available disease-modifying treatment strategies remained limited; thus, increasing demand for new drugs. In recent years, medicinal plants attracted attention due to their potential role in dementia. Read More

View Article and Full-Text PDF

Validation and demonstration of a new comprehensive model of Alzheimer's disease progression.

Alzheimers Dement 2021 May 14. Epub 2021 May 14.

Cognitive Neuroscience Division of the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.

Introduction: Identifying the course of Alzheimer's disease (AD) for individual patients is important for numerous clinical applications. Ideally, prognostic models should provide information about a range of clinical features across the entire disease process. Previously, we published a new comprehensive longitudinal model of AD progression with inputs/outputs covering 11 interconnected clinical measurement domains. Read More

View Article and Full-Text PDF

TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.

Alzheimers Dement 2021 May 14. Epub 2021 May 14.

Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium.

Introduction: Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively.

Methods: We performed genome-wide association studies (GWAS) using DNA and cerebrospinal fluid (CSF) samples from the EMIF-AD Multimodal Biomarker Discovery study for discovery, and the Alzheimer's Disease Neuroimaging Initiative study for validation analyses. GWAS were performed for all three CSF biomarkers using linear regression models adjusting for relevant covariates. Read More

View Article and Full-Text PDF

Cytoplasmic Mislocalization of RNA Polymerase II Subunit RPB1 in Alzheimer Disease Is Linked to Pathologic Tau.

J Neuropathol Exp Neurol 2021 May 15. Epub 2021 May 15.

From the Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts (JRD, HY, BTH); Harvard Medical School, Boston, Massachusetts (JRD, HY, MPF, BTH); C.S. Kubik Laboratory for Neuropathology, Department of Pathology, and Neurology Service, Massachusetts General Hospital, Boston, Massachusetts (MPF).

Abnormal protein accumulation and mislocalization is a general hallmark of Alzheimer disease. Recent data suggest nucleocytoplasmic transport may be compromised by tau in Alzheimer disease. In this context, we have examined the RNA polymerase II subunit RPB1, which is the catalytic subunit that plays a critical role in transcription. Read More

View Article and Full-Text PDF

Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer's disease.

Sci Rep 2021 May 14;11(1):10343. Epub 2021 May 14.

Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-Gu, Seoul, 05505, South Korea.

Imaging biomarkers support the diagnosis of Alzheimer's disease (AD). We aimed to determine whether combining automated brain volumetry on MRI and quantitative measurement of tau deposition on [18F] THK-5351 PET can aid discrimination of AD spectrum. From a prospective database in an IRB-approved multicenter study (NCT02656498), 113 subjects (32 healthy control, 55 mild cognitive impairment, and 26 Alzheimer disease) with baseline structural MRI and [18F] THK-5351 PET were included. Read More

View Article and Full-Text PDF

Pathological drivers of neurodegeneration in suspected non-Alzheimer's disease pathophysiology.

Alzheimers Res Ther 2021 May 14;13(1):100. Epub 2021 May 14.

Penn Memory Center, Department of Neurology, University of Pennsylvania, Philadelphia, USA.

Background: Little is known about the heterogeneous etiology of suspected non-Alzheimer's pathophysiology (SNAP), a group of subjects with neurodegeneration in the absence of β-amyloid. Using antemortem MRI and pathological data, we investigated the etiology of SNAP and the association of neurodegenerative pathologies with structural medial temporal lobe (MTL) measures in β-amyloid-negative subjects.

Methods: Subjects with antemortem MRI and autopsy data were selected from ADNI (n=63) and the University of Pennsylvania (n=156). Read More

View Article and Full-Text PDF

Synchrotron X-ray Fluorescence and FTIR Signatures for Amyloid Fibrillary and Nonfibrillary Plaques.

ACS Chem Neurosci 2021 May 14. Epub 2021 May 14.

Consorcio para la Construccion Equipamiento y Explotacion del Laboratorio de Luz Sincrotron, ALBA Synchrotron Light Source, Carrer de la Llum 2-26, 08290 Cerdanyola del Vallès, Catalonia, Spain.

Amyloid plaques are one of the principal hallmarks of Alzheimer's disease and are mainly composed of Aβ amyloid peptides together with other components such as lipids, cations, or glycosaminoglycans. The structure of amyloid peptide's aggregates is related to the peptide toxicity and highly depends on the aggregation conditions and the presence of cofactors. While fibrillary aggregates are nowadays considered nontoxic, oligomeric/granular (nonfibrillary) aggregates have been found to be toxic. Read More

View Article and Full-Text PDF

Fragile X-associated tremor/ataxia syndrome: pathophysiology and management.

Curr Opin Neurol 2021 May 14. Epub 2021 May 14.

Department of Pediatrics and MIND Institute, University of California Davis Health, Sacramento Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Davis, California, USA.

Purpose Of Review: The purpose of this paper is to review the prevalence, pathophysiology, and management of fragile X-associated tremor/ataxia syndrome (FXTAS).

Recent Findings: The pathophysiology of FXTAS involves ribonucleic acid (RNA) toxicity due to elevated levels of the premutation-expanded CGG (eoxycytidylate-deoxyguanylate-deoxyguanylate)-repeat FMR1 mRNA, which can sequester a variety of proteins important for neuronal function. A recent analysis of the inclusions in FXTAS demonstrates elevated levels of several proteins, including small ubiquitin-related modifiers 1/2 (SUMO1/2), that target molecules for the proteasome, suggesting that some aspect(s) of proteasomal function may be altered in FXTAS. Read More

View Article and Full-Text PDF

Sex differences in the association between the APOEε4 allele and hearing impairment: A longitudinal memory clinic study.

Arch Gerontol Geriatr 2021 May 11;95:104418. Epub 2021 May 11.

Department of Neurology, Dementia Center, Ilsan hospital, National Health Insurance Service, Goyang-shi, South Korea. Electronic address:

Background: The APOEε4 allele and hearing impairment are risk factors for dementia. Cross-sectional studies have shown controversial findings regarding the relationship between APOEε4 and hearing impairment. These may be explained by reported sex differences in the association between APOEε4 and some Alzheimer's disease biomarkers. Read More

View Article and Full-Text PDF

Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies.

Exp Neurol 2021 May 11:113756. Epub 2021 May 11.

Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900 Olomouc, Czech Republic. Electronic address:

Alzheimer's disease (AD) is characterised by the accumulation of intracytoplasmic aggregates of tau protein, which are suggested to spread in a prion-like manner between interconnected brain regions. This spreading is mediated by the secretion and uptake of tau from the extracellular space or direct cell-to-cell transmission through cellular protrusions. The prion-like tau then converts the endogenous, normal tau into pathological forms, resulting in neurodegeneration. Read More

View Article and Full-Text PDF

Effects of comprehensive intervention on life quality among the elderly with Alzheimer Disease and their caregivers based on mixed models.

Nurs Open 2021 May 14. Epub 2021 May 14.

Zhejiang Hospital, Hangzhou, China.

Aims: We conducted a multi-sectoral comprehensive intervention for elderly Alzheimer Disease patients and their caregivers to improve their quality of life.

Design: Randomized controlled trial.

Methods: From June to June in 2019, 150 Alzheimer Disease patients were randomly selected from a nursing home in Zhejiang province of China, they were randomly divided into the intervention group and the control group. Read More

View Article and Full-Text PDF

Alzheimer mutant speeds APP transport.

J Exp Med 2021 Jun 14;218(6). Epub 2021 May 14.

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY.

APPS198P segregates with rare familial forms of Alzheimer's disease and resides within exon 5, unlike 27 other mutations that reside in exons 16 or 17. In this issue, Zhang et al. (2021. Read More

View Article and Full-Text PDF

Individual Differences and Features of Self-reported Memory Lapses as Risk Factors for Alzheimer Disease Among Adults Aged 50 Years and Older: Protocol for a Coordinated Analysis Across Two Longitudinal Data Sets.

JMIR Res Protoc 2021 May 14;10(5):e25233. Epub 2021 May 14.

Edna Bennett Pierce Prevention Research Center, College of Health and Human Development, Pennsylvania State University, University Park, PA, United States.

Background: Increasing evidence has promoted the clinical utility of self-reported memory problems for detecting early impairment associated with Alzheimer disease (AD). However, previous studies investigating memory problems often conflated the types of problems (ie, retrospective and prospective) with their features (ie, frequency and consequences). This bias limits the specificity of traditional measures of memory problems and minimizes their ability to detect differential trajectories associated with cognitive decline. Read More

View Article and Full-Text PDF

Enhanced detection of cortical atrophy in Alzheimer's disease using structural MRI with anatomically constrained longitudinal registration.

Hum Brain Mapp 2021 May 14. Epub 2021 May 14.

Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Evansville, Indiana, USA.

Cortical atrophy is a defining feature of Alzheimer's disease (AD), often detectable before symptoms arise. In surface-based analyses, studies have commonly focused on cortical thinning while overlooking the impact of loss in surface area. To capture the impact of both cortical thinning and surface area loss, we used anatomically constrained Multimodal Surface Matching (aMSM), a recently developed tool for mapping change in surface area. Read More

View Article and Full-Text PDF

Endothelial genetic deletion of CD147 induces changes in the dual function of the blood-brain barrier and is implicated in Alzheimer's disease.

CNS Neurosci Ther 2021 May 13. Epub 2021 May 13.

Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China.

Aims: The blood-brain barrier (BBB) is a specialized and indispensable structure in brain blood vessels that is damaged during Alzheimer's disease (AD). CD147 is expressed on the BBB and deeply engaged in the AD pathological process. In this study, we aimed to provide a better understanding of the roles of CD147 in BBB function in health and neurodegenerative disease. Read More

View Article and Full-Text PDF

Individualized Prediction of Early Alzheimer's Disease Based on Magnetic Resonance Imaging Radiomics, Clinical, and Laboratory Examinations: A 60-Month Follow-Up Study.

J Magn Reson Imaging 2021 May 13. Epub 2021 May 13.

Department of Radiology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Background: Accurately predicting whether and when mild cognitive impairment (MCI) will progress to Alzheimer's disease (AD) is of vital importance to help developing individualized treatment plans to defer the occurrence of irreversible dementia.

Purpose: To develop and validate radiomics models and multipredictor nomogram for predicting the time to progression (TTP) from MCI to AD.

Study Type: Retrospective. Read More

View Article and Full-Text PDF

Cognitive and Structural Correlates of Conversational Speech Timing in Mild Cognitive Impairment and Mild-to-Moderate Alzheimer's Disease: Relevance for Early Detection Approaches.

Front Aging Neurosci 2021 27;13:637404. Epub 2021 Apr 27.

Trinity Centre for Biomedical Engineering, School of Engineering, Trinity College Dublin, Dublin, Ireland.

: Increasing efforts have focused on the establishment of novel biomarkers for the early detection of Alzheimer's disease (AD) and prediction of Mild Cognitive Impairment (MCI)-to-AD conversion. Behavioral changes over the course of healthy ageing, at disease onset and during disease progression, have been recently put forward as promising markers for the detection of MCI and AD. The present study examines whether the temporal characteristics of speech in a collaborative referencing task are associated with cognitive function and the volumes of brain regions involved in speech production and known to be reduced in MCI and AD pathology. Read More

View Article and Full-Text PDF

Comparing Pre-trained and Feature-Based Models for Prediction of Alzheimer's Disease Based on Speech.

Front Aging Neurosci 2021 27;13:635945. Epub 2021 Apr 27.

Winterlight Labs Inc., Toronto, ON, Canada.

Research related to the automatic detection of Alzheimer's disease (AD) is important, given the high prevalence of AD and the high cost of traditional diagnostic methods. Since AD significantly affects the content and acoustics of spontaneous speech, natural language processing, and machine learning provide promising techniques for reliably detecting AD. There has been a recent proliferation of classification models for AD, but these vary in the datasets used, model types and training and testing paradigms. Read More

View Article and Full-Text PDF

Alzheimer disease.

Nat Rev Dis Primers 2021 May 13;7(1):33. Epub 2021 May 13.

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants. AD is a common cause of cognitive impairment acquired in midlife and late-life but its clinical impact is modified by other neurodegenerative and cerebrovascular conditions. Read More

View Article and Full-Text PDF

Alzheimer disease.


Nat Rev Dis Primers 2021 May 13;7(1):34. Epub 2021 May 13.

View Article and Full-Text PDF

MRI-Visible Perivascular Spaces in the Centrum Semiovale Are Associated with Brain Amyloid Deposition in Patients with Alzheimer Disease-Related Cognitive Impairment.

AJNR Am J Neuroradiol 2021 May 13. Epub 2021 May 13.

From the Department of Nuclear Medicine (H.J.K., Y.H.R.), Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Background And Purpose: The association of perivascular spaces in the centrum semiovale with amyloid accumulation among patients with Alzheimer disease-related cognitive impairment is unknown. We evaluated this association in patients with Alzheimer disease-related cognitive impairment and β-amyloid deposition, assessed with [F] florbetaben PET/CT.

Materials And Methods: MR imaging and [F] florbetaben PET/CT images of 144 patients with Alzheimer disease-related cognitive impairment were retrospectively evaluated. Read More

View Article and Full-Text PDF

Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus.

Fluids Barriers CNS 2021 May 13;18(1):23. Epub 2021 May 13.

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy At the University of Gothenburg, Sahlgrenska University Hospital/Mölndal, 431 80, Mölndal, Sweden.

Background: Idiopathic normal pressure hydrocephalus (iNPH) is a reversible CNS disease characterized by disturbed cerebrospinal fluid (CSF) dynamics. Changes in the extracellular matrix (ECM) composition might be involved in the pathophysiology of iNPH. The aim of this study was to explore possible differences between lumbar and ventricular CSF concentrations of the ECM markers brevican and neurocan, matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase-1 (TIMP-1) and their relation to clinical symptoms in iNPH patients before and after shunt surgery. Read More

View Article and Full-Text PDF

Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).

Eur J Med Chem 2021 Apr 24;221:113492. Epub 2021 Apr 24.

LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal. Electronic address:

Alzheimer's disease (AD) is a chronic neurodegenerative disease and represents the major cause of dementia worldwide. Currently, there are no available treatments capable to deliver disease-modifying effects, and the available drugs can only alleviate the symptoms. The exact pathology of AD is not yet fully understood and several hallmarks such as the presence of amyloid-β (Aβ) senile plaques, neurofibrillary tangles (NFTs) as well as the loss of cholinergic function have been associated to AD. Read More

View Article and Full-Text PDF

Huprine Y - tryptophan heterodimers with potential implication to Alzheimer's disease treatment.

Bioorg Med Chem Lett 2021 May 10:128100. Epub 2021 May 10.

Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. Electronic address:

The search for novel and effective therapeutics for Alzheimer's disease (AD) is the main quest that remains to be resolved. The goal is to find a disease-modifying agent able to confront the multifactorial nature of the disease positively. Herewith, a family of huprineY-tryptophan heterodimers was prepared, resulting in inhibition of cholinesterase and neuronal nitric oxide synthase enzymes, with effect against amyloid-beta (Aβ) and potential ability to cross the blood-brain barrier. Read More

View Article and Full-Text PDF

Body mass index in early adulthood and dementia in late life: Findings from a pooled cohort.

Alzheimers Dement 2021 May 13. Epub 2021 May 13.

Departments of Psychiatry, Neurology, and Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

Introduction: To examine the independent association of body mass index (BMI) in early adulthood with dementia incidence among men and women.

Methods: We studied 5104 older adults from the Cardiovascular Health Study (CHS) and the Health, Aging, and Body Composition (Health ABC) study. We imputed early adulthood and midlife BMI using a pooled parent cohort with complete adult lifespan coverage and previously established methods. Read More

View Article and Full-Text PDF

Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults.

Alzheimers Dement 2021 May 13. Epub 2021 May 13.

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Introduction: Neurite orientation dispersion and density imaging (NODDI), a multi-compartment diffusion-weighted imaging (DWI) model, may be useful for detecting early cortical microstructural alterations in Alzheimer's disease prior to cognitive impairment.

Methods: Using neuroimaging (NODDI and T1-weighted magnetic resonance imaging [MRI]) and cerebrospinal fluid (CSF) biomarker data (measured using Elecsys® CSF immunoassays) from 219 cognitively unimpaired participants, we tested the main and interactive effects of CSF amyloid beta (Aβ) /Aβ and phosphorylated tau (p-tau) on cortical NODDI metrics and cortical thickness, controlling for age, sex, and apolipoprotein E ε4.

Results: We observed a significant CSF Aβ /Aβ × p-tau interaction on cortical neurite density index (NDI), but not orientation dispersion index or cortical thickness. Read More

View Article and Full-Text PDF

Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.

Alzheimers Dement 2021 May 13. Epub 2021 May 13.

National Institute of Mental Health, Bethesda, Maryland, USA.

Introduction: Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development.

Methods: A targeted, stable isotope, quantitative mass spectrometry-based investigation of longitudinal changes in concentrations of previously identified candidate biomarkers was performed in cerebrospinal fluid (CSF) of Alzheimer's Disease Neuroimaging Initiative participants who were classified as cognitively normal (CN; n = 76) or with mild cognitive impairment (MCI; n = 111) at baseline.

Results: Of the candidate biomarkers, the CSF concentration of neuronal pentraxin 2 (NPTX2), a protein involved in synaptic function, exhibited rates of change that were significantly different between three comparison groups (i. Read More

View Article and Full-Text PDF

Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.

Alzheimers Dement 2021 May 13. Epub 2021 May 13.

Clinical Memory Research Unit, Clinical Sciences, Malmö, Lund University, Malmö, Sweden.

Quality of life and health utility are important outcomes for patients with Alzheimer's disease (AD) and central for demonstrating the value of new treatments. Estimates in biomarker-confirmed AD populations are missing, potentially delaying payer approval of treatment. We examined whether health utility, assessed with the EuroQoL-5 3-level version (EQ-5D-3L), differed between individuals with a positive or negative amyloid beta (Aβ) biomarker in patients with mild cognitive impairment (MCI) and cognitively unimpaired (CU) participants from the Swedish BioFINDER study (n = 578). Read More

View Article and Full-Text PDF